Curcuma (Curcuma longa L.): A Comprehensive Reference
1. Identity: Botanical Classification, Names, and Plant Description
Botanical name: Curcuma longa L. (synonym: Curcuma domestica Valeton). Curcuma longa is a flowering plant in the ginger family Zingiberaceae. It is a perennial, rhizomatous, herbaceous plant native to the Indian subcontinent and Southeast Asia that requires temperatures between 20 and 30 °C and high annual rainfall to thrive. The common English name is turmeric; other culturally established names include Haldi in Hindi, manjal in Tamil, kunyit in Indonesian, Jianghuang in Chinese, and Kyoo in Japanese.
Genus context: More than 30 Curcuma species (Zingiberaceae) are found in Asia, where the rhizomes of these plants are used as both food and medicine, such as in traditional Chinese medicine. Among the Curcuma species, C. longa, C. aromatica, and C. xanthorrhiza are particularly well known. C. longa is thought to have arisen by selection and vegetative propagation of a hybrid between wild turmeric (Curcuma aromatica), native to India, Sri Lanka and the eastern Himalayas, and some other closely related species. The genus Curcuma includes other economically important species, including C. amada (mango ginger), C. angustifolia (wild arrowroot), and C. zedoaria (zedoary).
Morphology: Curcuma longa is an erect perennial herb, strongly tillering, up to 1.2 m tall. The rhizome is complex, with an ellipsoidal primary corm bearing numerous cylindrical, lateral rhizomes when mature; rhizomes are orange-yellow to bright orange, with young tips white. The aerial shoot bears 5–10 alternate, distichous leaves with blades that are oblong-lanceolate, up to 70 × 18 cm. Turmeric is sterile — it does not produce seed, but grows vigorously from the rhizomes. Propagation is by planting small rhizome pieces with 3–4 buds; the growing season extends from the late dry season to early rainy season, and rhizomes are harvested after at least 6–10 months.
Origin and cultivation: The exact origin of Curcuma longa is not known, but it is thought to originate from South or Southeast Asia, most probably Vietnam, China, or western India. It is only known as a domesticated plant and not found in the wild. It is native to India and now extensively cultivated in tropical and subtropical regions of South and Southeast Asia including China, Indonesia, and India, and some areas of Africa with a warm and wet tropical climate.
Etymology: The name Curcuma may derive from its Arabic name (kurkum) or the Hebrew name (karkom), meaning yellow. The term longa comes from the elongated shape of its rhizome.
Commercial forms and preparations: The dried rhizome of C. longa is the source for numerous product types used in food, pharmacy, and cosmetics. These include:
- Dried whole or sliced rhizome
- Turmeric powder (ground dried rhizome), used as a culinary spice and dye
- Standardized extracts, typically concentrated for curcuminoid content
- Isolated curcumin (pure curcuminoid fraction)
- Enhanced-bioavailability formulations: phytosomal preparations (e.g., Meriva®), lipid nanoparticle systems, nanoformulations, and preparations combined with piperine (bioperine)
- Topical preparations (ointments, pastes)
- Essential oil from the rhizome
The Chinese National Medical Products Administration's catalogue of cosmetic ingredients lists ten turmeric-derived ingredients, including Curcuma longa root, root powder, rhizome extract, root oil, root water, leaf extract, curcumin, and tetrahydrocurcumin.
2. Traditional and Historical Use
2.1 Age and Global Spread
According to records, the use of turmeric in India dated back roughly 6,000 years. It probably spread to both Morocco and China by around 700 AD, reached East Africa by 800 AD, and West Africa by 1200 AD. In the thirteenth century, Arab merchants brought turmeric to Europe.
2.2 Ayurveda and Indian Traditions
Turmeric has been used in Asia for centuries and is a major part of Ayurveda, Siddha medicine, traditional Chinese medicine, Unani, and the animistic rituals of Austronesian peoples. It was first used as a dye, and then later for its supposed properties in folk medicine. In Ayurvedic medicine, turmeric is a well-documented treatment for various respiratory conditions such as asthma, bronchial hyperactivity, and allergy, as well as for liver disorders, anorexia, rheumatism, diabetic wounds, runny nose, cough, and sinusitis. From ancient times, as prescribed by Ayurveda, turmeric has been used to treat sprains and swelling.
It appeared in Haridrakhand, a traditional sweet preparation still made today; in medicated ghees and oils; in herbal pastes applied externally; and in preparations combined with milk, honey, or warm water.
2.3 Traditional Chinese Medicine (TCM)
By around 700 CE, turmeric had made its way eastward into Chinese medicine, where it appears in classical texts under the name Jianghuang ("river yellow"). Traditional Chinese medicine valued the rhizome for its warming qualities and incorporated it into preparations aimed at supporting circulation and digestion. It was used to address what Chinese medicine termed stagnation — a concept loosely analogous to blockage or imbalance in the body's vital energy. In traditional Chinese medicine, it is used to treat diseases associated with abdominal pain.
2.4 Unani Medicine
In both Ayurvedic and traditional Chinese medicine, turmeric is considered a bitter digestive and a carminative. Unani practitioners also use turmeric to expel phlegm or kapha, as well as to open blood vessels in order to improve blood circulation.
2.5 Southeast Asia and Austronesian Peoples
In Maritime Southeast Asia, there is linguistic and circumstantial evidence of the ancient use of turmeric among the Austronesian peoples soon after dispersal from Taiwan (starting c. 3000 BCE), before contact with India. In Indonesia and the Philippines, turmeric was used for food, dyeing textiles, medicine, as well as body painting. Across Polynesia, turmeric has been used ceremonially as a body dye and sacred pigment for generations.
2.6 Early Modern Science
A turning point for the medical study of curcumin is usually dated to 1949, when Schraufstätter and Bernt published a paper in the journal Nature reporting the antibacterial action of curcumin and related compounds — one of the first modern scientific reports to test, rather than merely assume, a traditional therapeutic property of turmeric. Curcumin was first isolated in 1815 and structurally defined in 1910.
3. Key Constituents and Active Compounds
3.1 Curcuminoids
Turmeric, or Curcuma longa, is well known for a wide range of chemical components, chiefly a class of substances called curcuminoids. The most well-known of these is curcumin, which accounts for between 2 and 5% of the dried rhizome and is primarily responsible for turmeric's yellow hue and medicinal qualities. Diarylheptanoid derivatives, also known as curcuminoids — of which curcumin, demethoxycurcumin, and bisdemethoxycurcumin are the most important representatives — are the major active constituents of the plant rhizome.
Other curcuminoids isolated from Curcuma longa include demethoxycurcumin, bisdemethoxycurcumin, a cis-trans geometrical isomer of curcumin, and cyclocurcumin. Curcumin's full chemical name is diferuloylmethane, a polyphenolic compound belonging to the dicinnamoyl methane group.
Curcuminoids may be found in other botanicals in addition to Curcuma longa, such as Curcuma xanthorrhiza and Curcuma zedoaria.
3.2 Volatile Oils and Other Constituents
Curcumin, curcuminoids, ar-turmerone, α-turmerone, β-turmerone, and (z) β-ocimene, α-phellandrene, terpinolene, 1,8-cineole, undecanol, and p-cymene are among the major active constituents isolated from C. longa. Among phenolic components present in this plant, diarylheptanoids (curcuminoids), diarylpentanoids, vanillin, vanillic acid, and ferulic acid derivatives have been distinguished. Volatile compounds present in turmeric rhizome extracts are abundantly represented by different groups of terpenes, including monoterpene hydrocarbons, sesquiterpenes, and diterpenes.
The rhizome also contains proteins, carbohydrates, fats, and various micronutrients including vitamins C, B1, B2, and B3, and minerals such as sodium, iron, calcium, and potassium.
3.3 Broader Phytochemical Profile
Extensive research has confirmed that turmeric contains a variety of active ingredients, such as diphenylalkanoids, terpenoids, aromatics, steroids, fatty acids, minerals, and nucleosides.
4. Mechanisms of Action
4.1 Anti-Inflammatory Activity
Curcumin's anti-inflammatory effects involve the inhibition of key signaling pathways, such as those involving nuclear factor kappa-B (NF-κB) and cyclooxygenase-2 (COX-2). This property is probably mediated by curcumin's ability to block activation of the transcription factor NF-κB at the level of the NF-κB inducing kinase/IKKα/β signaling complex. Curcumin directly inhibits cyclooxygenase-2 and also inhibits the transcription of the gene responsible for its production. Cyclooxygenases (COX) catalyze the synthesis of prostaglandins from arachidonic acid.
4.2 Antioxidant Activity
Curcumin exhibits potent antioxidant properties by scavenging free radicals and modulating oxidative pathways to mitigate diseases associated with oxidative stress. Curcumin is a powerful antioxidant that increases the activity of endogenous antioxidant enzymes by scavenging free radicals and activating the Nrf2 pathway, which regulates cellular defense mechanisms.
4.3 Metabolic and Insulin-Related Pathways
Curcumin acts mainly as a signaling modulator that activates endogenous antioxidant responses such as the NRF2-KEAP1 pathway and has been demonstrated to reduce endoplasmic reticulum (ER) stress in a high-fat diet mouse model, in vitro in primary adipocytes, and in palmitate-induced insulin resistance in human umbilical vein endothelial cells. In clinical trials, curcumin as an effective antihyperglycemic agent has been found to improve insulin resistance and reduce insulin and blood glucose levels. Numerous studies have revealed that curcumin induces PPAR-γ activation to regulate glucose metabolism.
4.4 Neuroprotective Activity
Curcumin, the yellow polyphenolic pigment and the major component found in turmeric, possesses a wide spectrum of pharmacological and biological properties including antioxidant, anti-inflammatory, neuroprotective, anticarcinogenic, antibacterial, antidiabetic, chemoprotective, and immunomodulatory actions. Curcumin regulates numerous cytokines, transcription factors, adhesion molecules, protein kinases, redox status, and enzymes related to inflammation, which plays a principal role in most chronic illnesses.
4.5 Bioavailability — A Key Limitation
While curcumin has impressive pharmacological potential, its clinical utility faces challenges stemming from low aqueous solubility, poor stability in body fluids, a high rate of metabolism, rapid clearance, diminished gastrointestinal absorption, and constrained bioavailability. Various strategies have emerged to bolster curcumin's solubility and bioavailability, encompassing the use of curcumin analogues; the formation of chemical complexes with phospholipids, polysaccharides, or proteins; and the development of bioconjugates with substances such as turmeric oil. Piperine inhibits hepatic and intestinal glucuronidation and can increase curcumin's bioavailability by up to 2,000%.
5. Scientific Evidence by Health Area
5.1 Musculoskeletal: Osteoarthritis and Rheumatoid Arthritis
Osteoarthritis and other arthritic conditions represent the most extensively studied clinical application of curcumin in human trials.
A systematic review and meta-analysis incorporating 29 randomized controlled trials (RCTs) with 2,396 participants and 5 types of arthritis — including ankylosing spondylitis, rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, and gout/hyperuricemia — was conducted. Curcumin and Curcuma longa extract were administered in doses ranging from 120 mg to 1,500 mg for a duration of 4–36 weeks.
A further systematic review and meta-analysis demonstrated that curcumin led to a decrease in serum CRP and TNF-alpha levels in patients with knee osteoarthritis, though additional large-scale studies are recommended to further evaluate effects on proinflammatory biomarkers. More specifically, meta-analysis revealed that CRP (SMD = −0.906, 95% CI = −1.543 to −0.269, P = 0.005) and TNF-alpha (SMD = −0.921, 95% CI = −1.817 to −0.026, P = 0.044) levels were significantly lower in the curcumin group than in the placebo group; however, there were no significant differences in ESR, IL-1β, IL-6, or PGE-2 between groups.
Studies have demonstrated curcumin's anti-inflammatory, protective, and anti-apoptotic effects on chondrocytes. Curcumin has been shown to stimulate chondrocyte proliferation and collagen production while inhibiting matrix metalloproteinase activity. These mechanisms contribute to curcumin's ability to alleviate pain and improve joint function in osteoarthritis patients.
Several meta-analyses have evaluated oral turmeric or curcumin for osteoarthritis measures related to relieving knee pain and stiffness, increasing joint strength, and improving joint mobility. The initial evidence is positive; however, higher-quality evidence is needed to reach definitive conclusions, and more research is needed to understand the impact of bioavailability on curcumin's effects. Evidence strength: Moderate — positive signal across multiple RCT meta-analyses, with caveats about study heterogeneity and bioavailability variation.
5.2 Inflammatory Bowel Disease (IBD) and Gastrointestinal Health
Curcumin, a polyphenol derivative of the Curcuma longa rhizome, has received increasing attention in IBD due to its proposed anti-inflammatory, antioxidant, anticarcinogenic, and microbiome-altering effects.
Ulcerative colitis (UC): A landmark randomized, double-blind, multicenter trial involved UC maintenance therapy. Eighty-nine patients with quiescent UC were recruited; 45 received curcumin 1 g after breakfast and 1 g after the evening meal, plus sulfasalazine or mesalamine, while 44 received placebo plus sulfasalazine or mesalamine, for 6 months. A later meta-analysis comprised 9 RCTs including 507 patients with mild to moderate ulcerative colitis. While curcumin may improve activity index, clinical response, and endoscopic response in UC patients and reduce ESR and CRP, these findings require further confirmation.
One notable negative study reported no significant differences in rates of clinical remission, clinical response, mucosal healing, and treatment failure between curcumin and placebo at 8 weeks of treatment; discrepancies in drug dosage, drug delivery, and duration of treatment are among the postulated reasons for this outlier. Curcuminoids are lipophilic molecules and their absorption in the gastrointestinal tract can be low and variable. It is currently unclear whether the therapeutic effects of curcumin depend on its systemic bioavailability or are more the result of a topical action on the intestinal mucosa.
In a comprehensive meta-analysis, 13 placebo-controlled RCTs on curcumin treatment in IBD were included after screening 362 records. Evidence strength: Preliminary-to-moderate; most positive signal is in UC used as adjunct to conventional therapy; larger trials needed.
5.3 Metabolic Syndrome, Type 2 Diabetes, and Lipid Profiles
A review of meta-analyses of RCTs identified 54 meta-analyses of curcumin RCTs covering inflammation, antioxidant effects, glucose control, lipids, anthropometric parameters, blood pressure, endothelial function, depression, and cognitive function. A reduction in CRP levels was observed in seven of ten meta-analyses of RCTs.
Based on clinical studies and meta-analyses, curcumin/curcuminoid/turmeric might effectively lower fasting plasma glucose, HbA1c, triglycerides, total cholesterol, and LDL, but appears to show no effect in patients without a diabetic history. The compound shows no effect on improving systolic blood pressure or HDL-C.
In one meta-analysis, researchers failed to find significant reductions in systolic and diastolic blood pressure after curcumin intake (80–1,000 mg/day of curcumin, 320–2,400 mg/day of turmeric) for 8–24 weeks.
Evidence strength: Moderate for glycemic and lipid markers in patients with existing metabolic disease; weak to absent for blood pressure reduction.
5.4 Depression and Anxiety
Curcumin supplements exhibit antidepressant effects that may mitigate depression by modulating neurotransmitters and reducing inflammatory and oxidative stress pathways. One RCT evaluating the efficacy of curcumin in depression in obese type 2 diabetes patients employed a randomized, double-blind, placebo-controlled trial design with 227 participants.
In a review of meta-analyses, curcumin intake appeared to have positive effects on depression. In four of four meta-analyses, curcumin intake significantly improved depression. In one of two meta-analyses, curcumin intake significantly improved cognitive function.
Curcumin's efficacy in treating depression appears to be closely associated with both the duration of treatment and the formulation used. Future research should focus on identifying the optimal treatment protocols and formulation type to maximize curcumin's therapeutic potential in depression management. Duration analysis revealed significant effects for interventions lasting more than 8 weeks but not for shorter durations. Evidence strength: Preliminary-to-moderate; consistent signal across meta-analyses but most trials are small and heterogeneous.
5.5 Cognitive Function and Neuroprotection
Curcuma longa is a plant noted for its coloring, flavoring, and digestive properties, with biological activities primarily mediated by curcumin, which has potential in the prevention and treatment of age-related neurodegenerative disorders. Curcumin has shown significant antiaging activity through mechanisms including reducing oxidative radicals and enzymes in brain tissue, reducing cell aging, repairing damaged cardiovascular endothelium, reducing artery stiffness, and having a protective role against radiation damage.
In one of two meta-analyses reviewed, curcumin intake significantly improved cognitive function. Evidence strength: Weak-to-preliminary in humans; most neuroprotective data come from preclinical (animal and in vitro) studies; human RCT evidence is limited and inconsistent.
5.6 Liver Health
Curcumin has antioxidant, anti-inflammatory, and anti-apoptotic properties that are thought to help reduce liver toxicity. Various studies have been conducted on animals, with reports of curcumin improving markers of inflammation and liver transaminases. There has been increasing application to humans, with particular focus on curcumin use for prevention of metabolic dysfunction-associated steatotic liver disease. Meta-analyses and randomized controlled trials have reported improvements either in liver disease grade or significant reductions in liver transaminases and inflammatory cytokines. However, these studies have been limited by paucity of data, small sample sizes, short follow-up duration, and large inter-study heterogeneity. Evidence strength: Preliminary; positive preclinical and some positive RCT signals for NAFLD/MASLD, but limited by study quality.
5.7 Oncology (Cancer) — Chemopreventive Research
A clinical study on the effect of curcumin in patients with pancreatic cancer investigated the influence of curcumin on the expression of COX-2 and NF-κB. COX-2 expression levels decreased significantly after oral administration of 8 g curcumin/day. A downregulation of NF-κB was also observed but did not reach statistical significance. Despite the downregulation of both factors, no clinical response was observed in many patients; this was attributed to the measurement in peripheral blood mononuclear cells (PBMCs), which does not reflect what is occurring in the tumor itself. This study was not randomized and did not include a placebo group.
Findings across umbrella reviews suggest that curcumin has potentially positive effects on a range of outcomes including ulcerative colitis, liver and kidney function, rheumatoid arthritis, and painful conditions, but for many diseases the conclusions remain uncertain. Evidence strength: Very preliminary in oncology; preclinical and mechanistic data are extensive, but human clinical trial evidence remains limited and non-definitive. No clinical indication has been established for cancer treatment.
6. Dosage Forms and Doses Reported in Studies
The following dosages are reported from cited clinical and research sources and should not be interpreted as clinical recommendations:
- In arthritis RCTs, curcumin and Curcuma longa extract were administered in doses ranging from 120 mg to 1,500 mg per day for durations of 4–36 weeks.
- In a UC maintenance trial, patients received 1 g after breakfast and 1 g after the evening meal (2 g/day total), plus sulfasalazine or mesalamine, for 6 months.
- In a pancreatic cancer study, oral administration was at 8 g curcumin/day.
- In blood pressure and metabolic meta-analyses, doses of 80–1,000 mg/day of curcumin or 320–2,400 mg/day of turmeric were used for 8–24 weeks.
- Reported dietary consumption of turmeric in Asian countries is in the range of 200–1,000 mg/day, or 160–440 g/person/year. Intake in urban areas is lower (200 mg/day) than in rural areas (600 mg/day/person).
- Human double-blind clinical trials have demonstrated efficacy in rheumatoid arthritis at a dose of 1,200 mg curcuminoids/day for five to six weeks.
7. Body Systems and Health Areas Associated with Curcuma
The available evidence from umbrella reviews associates curcumin with potentially positive effects on lipid profiles, blood pressure, inflammatory markers and oxidative stress, musculoskeletal diseases, emotional and cognitive function, ulcerative colitis, liver and kidney function, primary dysmenorrhea or premenstrual syndrome, rheumatoid arthritis, and health-related quality of life.
- Musculoskeletal system: Osteoarthritis (knee), rheumatoid arthritis, ankylosing spondylitis, gout
- Gastrointestinal system: Ulcerative colitis, Crohn's disease (IBD), general digestive complaints, traditional use as a carminative and bitter digestive
- Metabolic system: Type 2 diabetes (glycemic control, insulin resistance), metabolic syndrome, dyslipidemia, NAFLD/MASLD
- Nervous system: Depression, anxiety, cognitive function, neuroprotection in neurodegenerative conditions (primarily preclinical)
- Cardiovascular system: Lipid profile improvement, endothelial function (preliminary data)
- Hepatic system: Hepatoprotection and liver enzyme improvement (animal and preliminary human data)
- Immune and oncological: Chemopreventive, immunomodulatory properties (largely preclinical)
- Integumentary (skin): Traditional topical use for wounds, anti-inflammatory skin preparations
8. Safety Considerations and Drug Interactions
8.1 General Safety of Conventional Preparations
Conventionally formulated oral turmeric or curcumin, not modified to enhance bioavailability, is likely safe in recommended amounts for up to 2 or 3 months. Oral turmeric can cause adverse effects such as nausea and vomiting, acid reflux, stomach upset, diarrhea, or constipation. Topical curcumin can cause hives or itching.
8.2 Hepatotoxicity — The Bioavailability-Linked Risk
Many curcumin products with increased bioavailability are on the market, and liver damage has been reported in some people who have consumed these bioavailable formulations. Isolated case reports and small case series of liver injury arising during use of turmeric dietary supplements have been published. Initially, these episodes were attributed to other exposures or possible contaminants. One reason given for the earlier safety and apparent lack of hepatotoxicity of curcumin was that it is poorly absorbed by the oral route, making it unclear whether there was adequate systemic exposure to achieve beneficial or adverse effects. Subsequently, means of increasing the bioavailability of curcumin were developed using piperine (black pepper) or lipid nanoparticle delivery methods to increase absorption.
Piperine inhibits hepatic and intestinal glucuronidation and can increase curcumin's bioavailability by up to 2,000%. However, this potentiation may also elevate the risk of hepatotoxicity, as reported in several recent cases involving turmeric-piperine combinations.
The enhanced drug bioavailability caused by piperine is due to its potent inhibition of drug metabolism, including inhibition of human P-glycoprotein and CYP3A4, while it interferes with UDP-glucose dehydrogenase and glucuronidation activities in the liver. While only a few cases of hepatotoxicity assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) have been reported from prolonged intake of piperine and curcumin, it is reasonable to speculate that suspected toxicity of Curcuma longa could be due to the concomitant presence of piperine itself.
The causality assessment of turmeric-associated drug-induced liver injury (DILI) is further complicated by the frequent presence of other hepatotoxic substances in commercial products. Investigations have found lead chromate in certain turmeric products, which may contribute to systemic and hepatotoxic risks.
There is a documented dichotomy between increasing reports of turmeric's hepatotoxicity and the existing literature on its potential hepatoprotective effects. The European Food Safety Authority (EFSA) identified 5 mg/kg per day as the no observed adverse effects level (NOAEL) for curcumin.
8.3 Interactions with Anticoagulant and Antiplatelet Drugs
The risk of bleeding might be increased because turmeric may interfere with clotting by decreasing platelet aggregation. Caution is warranted when turmeric or curcumin are taken with medicines or supplements that have anticoagulant or antiplatelet effects. Curcumin might decrease the clearance of warfarin from the body. Close monitoring is recommended if warfarin and curcumin are taken together, especially as warfarin has a narrow therapeutic index. A raised INR to a level associated with a serious risk of bleeding was reported in a person taking warfarin who also started to take a product containing turmeric; the person's INR measurements had previously been stable.
The mechanism behind this interaction involves curcumin's inhibition of platelet aggregation and its effects on cytochrome P450 enzymes that metabolize many medications, potentially increasing blood levels of anticoagulants.
8.4 Interactions with Antidiabetic and Antihypertensive Drugs
Turmeric or curcumin might reduce blood glucose and increase the risk of hypoglycemia. If a person has diabetes or takes herbal supplements that could reduce blood glucose levels, healthcare professional consultation is advised before starting turmeric or curcumin.
8.5 Pregnancy
The use of turmeric supplements during pregnancy may be unsafe.
8.6 Gastric Effects
Chronic dosing of curcuminoids may cause stomach distress and irritation due to the fact that curcuminoids act on prostaglandin production in a manner similar to that of aspirin and aspirin-like anti-inflammatory agents.
8.7 CYP3A4 Inhibition by Piperine in Combination Products
Piperine's inhibition of P-glycoprotein and CYP3A4 is a pharmacokinetic mechanism of particular concern in patients taking drugs metabolized by these pathways, as co-administration of piperine-containing curcumin products may alter plasma levels of co-administered pharmaceuticals.
References
Go back